Interestingly, the combination therapy exhibited marked antitumor efficacy in these HCC murine models (Fig. 6g–k and Supplementary Fig. S10a–h) and altered the immune landscape toward antitumor immunity, with decreased proportions of Tregs and MDSCs and increased proportions of IFN-γ+ and granzyme B+ CD8+ T cells (Fig. 6l–m). The gene discussed is GZMB; the disease is hepatocellular carcinoma.